- Home
- ONEW vs ZNTL Comparison
ONEW vs ZNTL Comparison
Compare ONEW & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONEW | ZNTL |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.4M | 156.7M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ONEW | ZNTL |
|---|---|---|
| Price | $10.28 | $3.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $16.75 | $6.60 |
| AVG Volume (30 Days) | 125.9K | ★ 578.2K |
| Earning Date | 04-28-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.87 |
| EPS | ★ 2.77 | N/A |
| Revenue | ★ $1,872,334,000.00 | $67,425,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.27 | N/A |
| P/E Ratio | $3.58 | ★ N/A |
| Revenue Growth | ★ 5.62 | N/A |
| 52 Week Low | $9.79 | $1.01 |
| 52 Week High | $18.15 | $3.95 |
Technical Indicators
Market Signals| Indicator | ONEW | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 35.53 | 64.75 |
| Support Level | N/A | $1.29 |
| Resistance Level | $12.51 | $3.95 |
| Average True Range (ATR) | 0.67 | 0.22 |
| MACD | -0.21 | 0.03 |
| Stochastic Oscillator | 32.24 | 97.50 |
Price Performance
Historical ComparisonAbout ONEW OneWater Marine Inc.
OneWater Marine Inc is a recreational marine retailer in the United States. The company operates in two segments: Dealership and Distribution. The Dealership segment is involved in selling new and pre-owned boats. It also arranges financing and insurance products, provides repairs and maintenance services, offers marine-related parts and accessories, and supplies slip and storage accommodations at certain locations. The Distribution segment focuses on the manufacturing, assembly, and distribution of marine-related products. These products are supplied to distributors, box retailers, and online retailers through a network of warehouses and distribution centers. The company generates the majority of its revenue from the Dealership segment.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.